meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - colorectal cancer (mCRC)
mCRC - 1st line (L1)
1
mCRC - 2nd line (L2)
3
endometrial cancer
1
esophageal cancer (EC)
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus lenvatinib
VEGF(R) inhibitor
lenvatinib
lenvatinib in association
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs anthracyclines
vs doxorubicin
vs taxanes
vs paclitaxel
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs paclitaxel plus carboplatin
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
pembrolizumab plus lenvatinib
title
doxorubicin
title
paclitaxel
title
KEYNOTE-775, 2022 NCT03517449 endometrial cancer 411/416
KEYNOTE-775, 2022 NCT03517449 endometrial cancer 411/416
Pathology:
endometrial cancer;
endometrial cancer
KEYNOTE-775, 2022
KEYNOTE-775, 2022
pembrolizumab plus lenvatinib
2
T1
T1
doxorubicin
0
T0
paclitaxel
0
T0